Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213440 | 0.87 | AKT1 (0.56) | AKT1KDM1AMAOBPTGDR2METAP2 | |
| SCHEMBL3838001 | 0.82 | AKT1 (0.53) | AKT1KDM1AMAOBMETAP2 | |
| SCHEMBL3837608 | 0.78 | AKT1 (0.58) | AKT1KDM1AMAOBPTGDR2METAP2 | |
| SCHEMBL2899390 | 0.75 | AKT1 (0.46) | AKT1AKT2 | |
| SCHEMBL14430129 | 0.73 | KDM1A (0.54) | AKT1KDM1AMAOBMETAP2AKT2 | |
| SCHEMBL1652625 | 0.73 | AKT1 (0.66) | AKT1KDM1AMAOBAKT2MALT1 | |
| SCHEMBL3840082 | 0.72 | AKT1 (0.59) | AKT1KDM1AMAOBPTGDR2AKT2 | |
| SCHEMBL5904305 | 0.71 | KDM1A (0.59) | AKT1KDM1AMAOBLRRK2 | |
| SCHEMBL30656042 | 0.71 | ADORA2A (0.50) | AKT1KDM1AMAOB | |
| SCHEMBL1939129 | 0.70 | AKT1 (0.64) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1631548-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1631548-B1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7414055-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414055-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1631548-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20060270673-A1 | Inhibitors of akt activity | MERCK & CO., INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1631548-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1622616-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096135-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096131-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270673-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | AKT1 1/4885KDM1A 2090/4885MAOB 3613/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | AKT1 5/4885KDM1A 1744/4885MAOB 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.